Form 4: SPRB CEO Acquires Shares via Employee Stock Plan

Spruce Biosciences CEO Javier B. Szwarcberg acquired 4,690 shares of common stock at $4.5305 per share through the company's Employee Stock Purchase Plan.

Summary

• Javier B. Szwarcberg, Chief Executive Officer and Director of Spruce Biosciences, Inc. (SPRB), acquired 4,690 shares of common stock.
• The transaction occurred on December 31, 2025, at an acquisition price of $4.5305 per share.
• The shares were acquired pursuant to the Issuer's 2020 Employee Stock Purchase Plan (ESPP).
• This acquisition is exempt under SEC Rules 16b-3(d) and 16b-3(c).
• Szwarcberg acquired the maximum allowable shares under Section 423 of the Internal Revenue Code.
• Following this transaction, Szwarcberg beneficially owns a total of 19,004 shares of Spruce Biosciences common stock.

Sentiment

Score: 7

Explanation: The CEO's acquisition of shares through an ESPP, particularly the maximum allowable, indicates confidence in the company's future prospects and aligns management's interests with shareholders. This is generally viewed positively by the market.

Positives

• CEO Javier B. Szwarcberg increased his direct ownership in Spruce Biosciences by acquiring 4,690 shares, signaling confidence in the company.
• The acquisition was made through an Employee Stock Purchase Plan, indicating participation in a broad-based employee benefit program.
• The CEO acquired the maximum allowable shares under Section 423 of the Internal Revenue Code, demonstrating strong commitment and belief in the company's future.

Future Outlook

N/A

Industry Context

N/A

Related Party Transactions

• Acquisition of shares by CEO Javier B. Szwarcberg through the company's 2020 Employee Stock Purchase Plan (ESPP), which is a standard employee benefit program.

Stakeholder Impact

• Shareholders: Increased alignment of the CEO's interests with shareholders due to increased direct ownership.
• Employees: The transaction highlights the existence and utilization of an Employee Stock Purchase Plan, a benefit available to employees.

Key Dates

Recommendation

The CEO's decision to acquire additional shares through the Employee Stock Purchase Plan, particularly the maximum allowable, signals confidence in Spruce Biosciences' future. This insider buying aligns management's interests with shareholders and is generally a positive indicator. However, a single Form 4 filing typically does not provide sufficient operational or financial detail to warrant a 'buy' or 'sell' recommendation without further analysis of the company's overall performance, market conditions, and strategic outlook. Therefore, a 'hold' recommendation is appropriate, acknowledging the positive signal while awaiting more comprehensive data.

Keywords

Spruce Biosciences, SPRB, Javier B. Szwarcberg, CEO, Director, Insider Trading, Stock Purchase, ESPP, Form 4, SEC Filing, Equity Acquisition